Tiantan Biological Products greenlights entrusted loans for subsidiaries

Beijing Tiantan Biological Products Co. Ltd. (SSE:600161) announced that it will extend entrusted loans totaling up to CNY 397 million to its subsidiaries. The decision, approved during the company's Ninth Board of Directors' 21st meeting and detailed in a legal opinion by Beijing Jiayuan Law Firm, aims to support the business development of its subsidiaries: Kunming Blood Products, Guizhou Biopharmaceutical, Lanzhou Biopharmaceutical, and Shanghai Blood Products. The loans, facilitated through China National Pharmaceutical Group Finance Co., Ltd. (CNPG Finance), will carry an annual interest rate benchmarked against the one-year Loan Prime Rate (LPR). The board also ratified the election of Ms. Zhang Jieming and Ms. Wang Qi as directors. With the entrusted loans, Tiantan Biologicals ensures the financial well-being and operational capabilities of its subsidiaries amid evolving market dynamics.